"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves fam-trastuzumab deruxtecan-nxki (Enhertu) for unresectable or metastatic HER2-positive breast cancer

FDA Approves fam-trastuzumab deruxtecan-nxki (Enhertu) for unresectable or metastatic HER2-positive breast cancer

07 Jan 2020 1:19 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software